Company ContraVir Pharmaceuticals Inc Nasdaq
Equities
US21234W2026
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 15-12-31 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-02 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 19-10-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 13-05-14 |
Timothy Block
BRD | Director/Board Member | 69 | 13-11-25 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 22-06-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,688 | 0 | 0 | 99.69 % |
Stock B | 1 | 5,472,451 | 5,455,670 ( 99.69 %) | 0 | |
Stock C | 0 | 85,581 | 0 | 0 |
Company contact information
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.comSector
1st Jan change | Capi. | |
---|---|---|
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |